QT Vascular said it acquired a new technology platform created by an undisclosed developer in Israel called Java that it plans to develop as an aortic valvuloplasty balloon for transcatheter aortic valve implants.
Singapore-based QT Vascular said the technology is designed to be a highly deliverable, puncture-resistant device with proprietary tines that aid in stability and reduce the need for peri-procedural cardiac pacing.
"The acquisition of the Java technology will open new market opportunities for us and is consistent with our corporate strategy of maintaining a strong pipeline of high value and differentiated products," CEO Dr. Eitan Konstantino said in prepared remarks. "With the advent of TAVI, there is now a resurgence of interest in valvuloplasty as a means of optimizing the outcomes in these very expensive procedures. We believe Java’s revolutionary design will allow it to play a unique role as the number of TAVI procedures continues to grow."
In mid-September, QT Vascular announced the enrollment of the 1st European patient in a clinical trial of its Chocolate Touch drug-coated peripheral balloon platform designed to provide predictable, uniform and less-traumatic dilatation.
In June, QT Vascular subsidiary TriReme Medical received FDA clearance to market the Chocolate PTCA balloon catheter for the treatment of blocked arteries for coronary vascular diseases.